Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT trial for focal knee cartilage lesions
NL-OMON55402Phase 3Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous chondrons + allogeneic mesenchymal stromal cells in chondral knee defect (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Clinical improvement by KOOS and Quality of life by EQ-5D. Started Jul 2019; status: completed.
02
Drugs
autologous chondrons + allogeneic mesenchymal stromal cells
03
Conditions
chondral knee defect
Beyond the preview
Go deeper on NL-OMON55402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55402.